TCF19

Across TCGA pan-cancer cohorts, TCF19 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated TCF19 data layer compared with 3 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TCF19 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCF19 expression acts as an unfavorable survival marker, although some lineages such as THYM and UVM show a favorable association.

ACC, KIRP, and MESO are the cancer types where TCF19 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.220	0.663	<.001	134	view →
KIRP	DFS	Tertile	All	0.756	0.939	<.001	92	view →
MESO	OS	Median	All	0.405	0.675	<.001	90	view →
KICH	DFS	Median	III,IV	0.259	0.943	<.001	80	view →
LIHC	DFS	Median	All	0.453	0.628	<.001	71	view →
LGG	OS	Median	All	0.712	0.910	<.001	54	view →
PAAD	OS	Tertile	All	0.268	0.541	<.001	47	view →
BRCA	OS	Median	II,III,IV	0.887	0.934	.003	35	view →
SARC	OS	Median	All	0.439	0.730	<.001	29	view →
UCEC	OS	Quartile	All	0.834	0.939	.003	28	view →
SKCM	OS	Median	All	0.244	0.392	.001	23	view →
THYM	OS	Median	All	0.966	0.701	<.001	23	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

TCF19–ACC (DFS)

Open the ACC breakdown →